| Subject: | FDA Issues Recommendations Regarding NSAID Use |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Fri, 7 Jan 2005 - 10:00 am |
| The FDA has issued several statements recently regarding the use of Cox-2 selective non-steroidal anti-inflammatory (NSAID) medications. These statements focused on the increased risk of cardiovascular events in patients taking Cox-2 selective agents (also called Cox-2 inhibitors). Additionally, the FDA has identified that long-term use of the non-selective NSAID, naproxen (sold as OTC Aleve, Naprosyn and other trade name and generic products), may be associated with an increased cardiovascular... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. Other vendors have components of legislated requirements available online or on CD-ROM. However there is no other product that marries regulatory agency mandates with implementation tools, making the latest compliance information immediately available online. No other product provides an interpretative analysis, followed by a practical application tool, therefore providing users with an immediate solution to compliance problems. StayAlert! includes operational components for healthcare organizations, allowing complete facility compliance with mandated requirements, online. |
|
